Present Indications and Results of Radiotherapy in Non-Hodgkin’s Lymphomas

  • Mauro G. Trovò
  • Roberto Bortolus
Conference paper
Part of the ESO Intercity Report book series (ESO INTERCITY)


Non-Hodgkin’s Lymphomas (NHL) are a very complex group of diseases and there are many reasons which prevent the physician from confidently being able to base management decisions on published data from studies on NHL. The choice of treatment requires a balancing of radiation therapy (RT) with systemic chemotherapy (CT). In some cases, RT alone may be sufficient, whereas in the presence of advanced disease or of unfavourable histologies a large number of patients have to be managed with CT, either alone or in combination with RT.


Princess Margaret Hospital Total Lymphoid Irradiation EORTC Trial Unfavourable Histology Diffuse Histiocytic Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tubiana M, Carde P, Burgers JMV, Cosset JM, Van Glabbeke M, Somers R: Prognostic factors in non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 1985(12):503–514Google Scholar
  2. 2.
    Jones SE, Fuks Z, Kaplan HS, et al: Non-Hodgkin’s lymphomas. Results of radiotherapy. Cancer 1973 (32):682PubMedCrossRefGoogle Scholar
  3. 3.
    Carbone PP, Kaplan HS, Musshof K, et al: Report of the Committee on Hodgkin’s disease staging classification. Cancer Res 1971 (31):1860PubMedGoogle Scholar
  4. 4.
    Rappaport H: Tumors of the hematopoietic system. In: Atlas of Tumor Pathology, section 3, Fasc. 8. Armed Forces Institute of Pathology, Washington 1966Google Scholar
  5. 5.
    The Non-Hodgkin’s Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982 (49):2112CrossRefGoogle Scholar
  6. 6.
    Fuks Z, Kaplan HS: Recurrence rates following radiation therapy of nodular and diffuse lymphomas. Radiology 1973 (108):675PubMedGoogle Scholar
  7. 7.
    Lukes RJ, Collins RD: New approaches to the classification of the lymphomata. Br J Cancer 1975 (3-Suppl 2):1Google Scholar
  8. 8.
    Castellani R, Bonadonna G, Spinelli R, Baietta E, Galante E, Rilke F: Sequential pathologic staging of untreated non-Hodgkin’s lymphomas by laparoscopy and laparotomy combined with marrow biopsy. Cancer 1977 (40):2322–2328PubMedCrossRefGoogle Scholar
  9. 9.
    Chabner BA, Johnson RE, Young RC, Canellos GP, Hubbard SP, Johnson SK, De Vita VT Jr: Sequential non surgical and surgical staging of non-Hodgkin’s lymphomas. Ann Intern Med 1976 (85):149–154PubMedGoogle Scholar
  10. 10.
    Goffinet DR, Warnke R, Dunnick NR, Castellino R, Glatstein E, Nelsen PS, Dorfman RF, Rosenberg SA, Kaplan HS: Clinical and surgical (laparotomy) evaluation of patients with non-Hodgkin’s lymphomas. Cancer Treat Rep 1977 (61):981–992PubMedGoogle Scholar
  11. 11.
    Hoppe RT: The role of radiation therapy in the management of the non-Hodgkin’s lymphomas. Cancer 1985 (55):2176–2183PubMedCrossRefGoogle Scholar
  12. 12.
    Sutcliffe SB, Gospodarowicz MK, Bush RS, Brown TC, Chua T, Bean HA, Clark RM, Dembo A, Fitzpatrick PJ, Peters MV: Role of radiation therapy in localized non-Hodgkin’s lymphoma. Radiother Oncol 1985 (4):211–223PubMedCrossRefGoogle Scholar
  13. 13.
    Glatstein E, Wasserman TH: Non-Hodgkin’s Lymphomas. In: Perez C, Brady WL (eds) Principles and Practice of Radiation Oncology. JB Lippincott, Philadelphia 1987 pp 1073–1085Google Scholar
  14. 14.
    Somers R, Burgers JMV, Qasim M, Van Glabbeke M, Duez N, Hayat M: EORTC trial non-Hodgkin Lymphomas. Eur J Cancer Clin Oncol 1987 (23):283–293PubMedCrossRefGoogle Scholar
  15. 15.
    Paryani SB, Hoppe RT, Cox RS, Colby TV, Rosenberg SA, Kaplan HS: Analysis of non-Hodgkin’s lymphomas with nodular and favourable histologies, stage I and II. Cancer 1983 (52):2300–2307PubMedCrossRefGoogle Scholar
  16. 16.
    Gospodarowicz MK, Bush RS, Brown TC, Chua T: Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1981 (10):489–497Google Scholar
  17. 17.
    Levitt SH, Bloomfield CD, Frizzera G, Lee CKK: Curative radiotherapy for localized diffuse histiocytic lymphoma. Cancer Treat Rep 1980 (64):175–177PubMedGoogle Scholar
  18. 18.
    Suit DL, Golomb HN: The treatment of histiocytic lymphoma. Semin Oncol 1980 (7):302–309Google Scholar
  19. 19.
    Bonadonna G, Lattuada A, Banfi A: Recent trends in the medical treatment of non-Hodgkin’s lymphomas. Europ J Cancer 1976 (12): 661–673Google Scholar
  20. 20.
    Bush RS, Gospodarowicz M, Sturgeon J, Alison R: Radiation therapy of localized non-Hodgkin’s lymphoma. Cancer Treat Rep 1977 (61):1129PubMedGoogle Scholar
  21. 21.
    Lamb DS, Vaughan Hudson G, Easterling MJ, MacLennan KA, Jelliffe AM: Localised grade 2 non-Hodgkin’s lymphoma: results of treatment of radiotherapy (BNLI report n. 24). Clinical Radiol 1984 (35):253–260CrossRefGoogle Scholar
  22. 22.
    Mill WB, Lee FA, Franssila KO: Radiation therapy of stage I and II extranodal non-Hodgkin’s lymphoma of the head and neck. Cancer 1980 (45):653–661PubMedCrossRefGoogle Scholar
  23. 23.
    Peckham MJ, Guay JP, Hamlin IME, Lukes RJ: Survival in localised nodal and extranodal non-Hodgkin’s lymphomata. Br J Cancer 1975 (31):413–424CrossRefGoogle Scholar
  24. 24.
    Phillips DL: Radiotherapy in the treatment of localised non-Hodgkin’s lymphomas. (BNLI Report n. 16). Clin Radiol 1981 (32):543–546PubMedCrossRefGoogle Scholar
  25. 25.
    Reddy S, Saxena VR, Pellettiere EV, Hendrickson FR: Early nodal and extranodal non-Hodgkin’s lymphomas. Cancer 1977 (40):98–104PubMedCrossRefGoogle Scholar
  26. 26.
    Fuks Z, Glatstein E, Kaplan HS: Patterns of presentation and relapse in the non-Hodgkin’s lymphomata. Br J Cancer 1975 (31):286–297Google Scholar
  27. 27.
    Monfardini S, Banfi A, Bonadonna G, Rilke F, Milani F, Valagussa P, Lattuada A: Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin’s lymphomas. Int J Radiat Oncol Biol Phys 1980 (6):125–134PubMedCrossRefGoogle Scholar
  28. 28.
    Bajetta E, Valagussa P, Bonadonna G, Lattuada A, Buzzoni R, Rilke F, Banfi A: Combined modality treatment for stage I-II non-Hodgkin’s lymphomas: CVP versus Bacop chemotherapy. Int J Radiat Oncol Biol Phys 1988 (15):3–12PubMedCrossRefGoogle Scholar
  29. 29.
    Nissen NI, Ersboll J, Hansen HS, Walbom-Jorgensen S, Pedersen-Bjergaard J, Hansen MM, Rygard J: A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin’s lymphomas. Cancer 1983 (52):1–7PubMedCrossRefGoogle Scholar
  30. 30.
    Landberg TG, Hakansson LG, Moller TR, Mattsson WKI, Landys KE, Johansson BG, Killander DCF, Molin BF, Westling PF, Lenner PH, Dahl OG: CVP-remission-maintenance in stage I or II non-Hodgkin’s lymphomas. Preliminary results of a randomized study. Cancer 1979 (44):831–838PubMedCrossRefGoogle Scholar
  31. 31.
    Cosset JM, Ozanne F, Henry-Amar M, Carde P, Amiel JL, Hayat M, Habrand JL, Tubiana M: An alternating chemotherapy and radiotherapy combination for non-Hodgkin’s lymphomas of unfavourable histologies: feasibility and preliminary results. Radiother Oncol 1985 (3):133–138PubMedCrossRefGoogle Scholar
  32. 32.
    O’Connell MJ, Harrington DP, Earle JD, Johnson GJ, Glick JH, Neiman RS, Silverstein MN: Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage II aggressive histologic type non-Hodgkin’s lymphoma. Cancer 1988 (61):1754–1758PubMedCrossRefGoogle Scholar
  33. 33.
    Glatstein E, Donaldson SS, Rosenberg SA, Kaplan HS: Combined modality treatment in malignant lymphomas. Cancer Treat Rep 1977 (61):1199–1207Google Scholar
  34. 34.
    Hoppe RT, Kushlan P, Rosenberg SA, Kaplan HS: The treatment of advanced stage favorable histology non-Hodgkin’s lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 1981 (58):592–598PubMedGoogle Scholar
  35. 35.
    Rosenberg SA: The low grade non-Hodgkin’s lymphomas: challenges and opportunities. J Clin Oncol 1985 (3):299–310PubMedGoogle Scholar
  36. 36.
    Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin lymphomas. New Engl J Med 1984 (311):1476–1481CrossRefGoogle Scholar
  37. 37.
    McKelvey EM, Gottlieb JA, Wilson HE et al: Hydroxydaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976 (38):1484–1493PubMedCrossRefGoogle Scholar
  38. 38.
    Fisher RI, Dahlberg S, Miller TP, Jones SE, Coltman CA: Long term survival of patients with nodular histiocytic (NH), diffuse poorly differentiated lymphocytic (DPDL), diffuse mixed (DM) and diffuse undifferentiated lymphoma treated with CHOP chemotherapy. Proceedings A.S.C.O. Vol. 8 March 1989, #1003Google Scholar
  39. 39.
    Gordon LI, Harrington D, Glick JH, Colgan J, O’Connell M, Oken M, Resnick G, Anderson J, Gottlieb A for ECOG and CALGB: Randomized phase III comparison of CHOP vs m-BACOD in diffuse large cell (DH) and diffuse mixed (DM) lymphoma: equivalent complete response (CR) rates and time to treatment failure but greater toxicity with m-BACOD. Proceedings A.S.C.O. Vol. 8 March 1989, #995Google Scholar
  40. 40.
    Wieck J, Dahlberg S, Miller T, Dana B, Fisher R: The treatment of non-Hodgkin’s lymphoma with m-BACOD, ProMACE-CytaBOM, and MACOP-B: The Southwest Oncology Group (SWOG) experience. Proceeding A.S.C.O. Vol. 8 March 1989, # 990Google Scholar
  41. 41.
    Chisesi T, Santini G, Congiu A, Sertoli MR, Porcellini A, Rizzoli V, Coser P, Ardizzoni A, Contu A for the Italian NHL Cooperative Study Group (NHLCSG): Alternating promace/MOP chemotherapy in intermediate and high-grade diffuse non-Hodgkin’s lymphomas (NHL). Proceedings A.S.C.O. Vol. 8 March 1989, #1059Google Scholar
  42. 42.
    Jones SE, Salmon S, Fisher R: Adjuvant immunotherapy with BCG in non-Hodgkin’s lymphoma: a Southwest Oncology Group controlled clinical trial. In: Jones SE, Salmon S (eds) Adjuvant Therapy of Cancer II. Grune and Stratton, New York 1979 pp 163–171Google Scholar
  43. 43.
    Canetta R et al: Sequential non-cross-resistant regimens (CVP and ABP) in advanced non-Hodgkin lymphomas. Proc Am Assoc Cancer Res 1980 (21):189Google Scholar
  44. 44.
    Laurence J et al: Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Annals of Internal Medicine 1982 (97):190–195PubMedGoogle Scholar
  45. 45.
    Skarin AT et al: Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-MACOD). J Clin Oncol 1983 (1):91–98PubMedGoogle Scholar
  46. 46.
    Fisher RI et al: Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOP chemotherapy. Ann Int Med 1983 (98):304–309PubMedGoogle Scholar
  47. 47.
    Cabanillas F et al: Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. Am J Med 1983 (74):382–388PubMedCrossRefGoogle Scholar
  48. 48.
    Connors JM, Klimo P: Cancer Control Agency of British Columbia Vancouver, BC Canada V5Z 3J3 1984 MACOP-B treatment of advanced diffuse large cell lymphoma 1984Google Scholar
  49. 49.
    Tirelli U, Zagonel V, Serraino D, Thomas J, Hoerni B, Tanguri A, Ruhl, Bey P, Tubiana M, Breed WPM, Roozendaal KJ, Hagenbeek A, Hupperets PS, Somers R: Non-Hodgkin’s lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group Study. J Clin Oncol 1988 (6):1708–1713PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Mauro G. Trovò
    • 1
  • Roberto Bortolus
    • 1
  1. 1.Department of RadiotherapyCentro di Riferimento OncologicoAvianoItaly

Personalised recommendations